• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新冠病毒二次感染患者的临床和流行病学特征:一项系统综述

Clinical and epidemiological features of patients with COVID-19 reinfection: a systematic review.

作者信息

Toro-Huamanchumo C J, Hilario-Gomez M M, Pinedo-Castillo L, Zumarán-Nuñez C J, Espinoza-Gonzales F, Caballero-Alvarado J, Rodriguez-Morales A J, Barboza J J

机构信息

Universidad César Vallejo, Trujillo, Peru.

Sociedad científica de San Fernando, Universidad Nacional Mayor de San Marcos, Lima, Peru.

出版信息

New Microbes New Infect. 2022 Jul;48:101021. doi: 10.1016/j.nmni.2022.101021. Epub 2022 Aug 28.

DOI:10.1016/j.nmni.2022.101021
PMID:36060548
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9420201/
Abstract

Recurrent positivity in a patient with COVID-19 may be due to various reasons, not necessarily reinfection. There is concern about the occurrence frequency of reinfection. Five databases and a preprint/preprint repository were searched. All case reports, case series, and observational studies were included. Bias was assessed for each study with the Newcastle-Ottawa Scale tool and reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA-2020). After eligibility, 77 studies were included for qualitative synthesis (52 case reports, 21 case series, and four case-controls; 1131 patients included). Of these, 16 studies described a second contact with the SARS-CoV-2 positive case, five studies described healthcare profession-related infection, ten studies described that the source of reinfection was likely to be from the community, one study described travel-related infection, nine studies described vulnerability-related infection due to comorbidity. The mean number of days from discharge or negative test to reinfection ranged from 23.3 to 57.6 days across the different included studies. The risk of bias for all case report/series studies was moderate/high. For observational studies, the risk of bias was low. Reinfection of patients with COVID-19 occurs between the first and second month after the first infection, but beyond, and 90 days have been proposed as a point to begin to consider it. The main factor for reinfection is contact with COVID-19 positive cases.

摘要

新型冠状病毒肺炎(COVID-19)患者反复出现阳性可能有多种原因,不一定是再次感染。人们对再次感染的发生频率感到担忧。检索了五个数据库和一个预印本/预印本储存库。纳入了所有病例报告、病例系列和观察性研究。使用纽卡斯尔-渥太华量表工具对每项研究的偏倚进行评估,并根据系统评价和Meta分析的首选报告项目(PRISMA-2020)进行报告。在符合纳入标准后,纳入77项研究进行定性综合分析(52项病例报告、21项病例系列和4项病例对照研究;共纳入1131例患者)。其中,16项研究描述了与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)阳性病例的二次接触,5项研究描述了与医疗职业相关的感染,10项研究描述再次感染的来源可能来自社区,1项研究描述了与旅行相关的感染,9项研究描述了由于合并症导致的与易感性相关的感染。在不同的纳入研究中,从出院或检测阴性到再次感染的平均天数为23.3至57.6天。所有病例报告/系列研究的偏倚风险为中度/高度。对于观察性研究,偏倚风险较低。COVID-19患者的再次感染发生在首次感染后的第一个月至第二个月之间,但也可能在之后发生,有人提出90天作为开始考虑再次感染的时间点。再次感染的主要因素是接触COVID-19阳性病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f7/9554825/3e2f2b8bc2cb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f7/9554825/3e2f2b8bc2cb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/39f7/9554825/3e2f2b8bc2cb/gr1.jpg

相似文献

1
Clinical and epidemiological features of patients with COVID-19 reinfection: a systematic review.新冠病毒二次感染患者的临床和流行病学特征:一项系统综述
New Microbes New Infect. 2022 Jul;48:101021. doi: 10.1016/j.nmni.2022.101021. Epub 2022 Aug 28.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Reinfection risk of novel coronavirus (COVID-19): A systematic ‎review of current evidence.新型冠状病毒(COVID-19)的再感染风险:当前证据的系统评价
World J Virol. 2020 Dec 15;9(5):79-90. doi: 10.5501/wjv.v9.i5.79.
4
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.先前感染 SARS-CoV-2 和混合免疫对奥密克戎变异株和重症疾病的保护效力:系统评价和荟萃回归分析。
Lancet Infect Dis. 2023 May;23(5):556-567. doi: 10.1016/S1473-3099(22)00801-5. Epub 2023 Jan 18.
5
The prevalence of adaptive immunity to COVID-19 and reinfection after recovery - a comprehensive systematic review and meta-analysis.COVID-19 适应性免疫和康复后再感染的流行情况——一项全面的系统评价和荟萃分析。
Pathog Glob Health. 2022 Jul;116(5):269-281. doi: 10.1080/20477724.2022.2029301. Epub 2022 Jan 31.
6
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.新冠康复者血浆或超免疫球蛋白用于新冠患者:快速综述
Cochrane Database Syst Rev. 2020 May 14;5(5):CD013600. doi: 10.1002/14651858.CD013600.
7
Recurrent and persistent infection with SARS-CoV-2 - epidemiological data and case reports from Western Sweden, 2020.2020 年,瑞典西部复发性和持续性 SARS-CoV-2 感染的流行病学数据和病例报告。
Infect Dis (Lond). 2021 Nov-Dec;53(12):900-907. doi: 10.1080/23744235.2021.1957143. Epub 2021 Jul 24.
8
Frontliners on the Move: A Quantitative Analysis of the Prevalence of COVID-19 Reinfection Among Healthcare Workers.前线人员动态:医护人员中新冠病毒再感染率的定量分析
Cureus. 2022 May 1;14(5):e24652. doi: 10.7759/cureus.24652. eCollection 2022 May.
9
[COVID-19 recurrence due to reinfection with SARS-CoV-2 in a hemodialysis patient: there and back again].[一名血液透析患者因再次感染严重急性呼吸综合征冠状病毒2导致新型冠状病毒肺炎复发:去而复返]
G Ital Nefrol. 2022 Apr 21;39(2):2022-vol2.
10
Clinical Presentation of Cases with SARS-CoV-2 Reinfection/ Reactivation.SARS-CoV-2 再感染/再激活病例的临床表现。
J Assoc Physicians India. 2021 Jan;69(1):16-18.

引用本文的文献

1
Burden in Colombia of COVID-19 in Adults and the Associated Clinical Characteristics: A Retrospective Database Analysis.哥伦比亚成年人中新冠病毒病的负担及相关临床特征:一项回顾性数据库分析
Trop Med Infect Dis. 2025 May 22;10(6):146. doi: 10.3390/tropicalmed10060146.
2
Next generation sequencing of multiple SARS-CoV-2 infections in the Omicron Era.奥密克戎时代多重新冠病毒感染的下一代测序
Sci Rep. 2025 Jan 27;15(1):3372. doi: 10.1038/s41598-024-84952-6.
3
Insights from an N3C RECOVER EHR-based cohort study characterizing SARS-CoV-2 reinfections and Long COVID.

本文引用的文献

1
Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: A systematic review and meta-analysis.COVID-19 再感染、复发和住院病例的流行病学特征:系统评价和荟萃分析。
J Med Virol. 2022 Jan;94(1):44-53. doi: 10.1002/jmv.27281. Epub 2021 Aug 27.
2
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明:系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
3
COVID-19 Reinfection.新冠病毒二次感染
一项基于N3C RECOVER电子健康记录的队列研究对SARS-CoV-2再感染和长期新冠的见解。
Commun Med (Lond). 2024 Jul 11;4(1):129. doi: 10.1038/s43856-024-00539-2.
4
Evaluation of SARS-CoV-2-Positive Patients with Suspected Reinfection.评估疑似再感染 SARS-CoV-2 阳性患者。
Viruses. 2023 Nov 7;15(11):2222. doi: 10.3390/v15112222.
5
SARS-CoV-2 reinfection: Adding insult to dysfunctional endothelium in patients with atherosclerotic cardiovascular disease.严重急性呼吸综合征冠状病毒2型再感染:给动脉粥样硬化性心血管疾病患者本就功能失调的内皮增加损伤。
Atheroscler Plus. 2023 Sep;53:1-5. doi: 10.1016/j.athplu.2023.06.002. Epub 2023 Jun 2.
6
Early SARS-CoV-2 Reinfections Involving the Same or Different Genomic Lineages, Spain.西班牙早期涉及相同或不同基因组谱系的 SARS-CoV-2 再感染。
Emerg Infect Dis. 2023 Jun;29(6):1154-1161. doi: 10.3201/eid2906.221696. Epub 2023 May 2.
7
SARS-CoV-2 Reinfection is Preceded by Unique Biomarkers and Related to Initial Infection Timing and Severity: an N3C RECOVER EHR-Based Cohort Study.严重急性呼吸综合征冠状病毒2型再次感染之前存在独特生物标志物,且与初次感染时间及严重程度相关:一项基于国家COVID-19合作临床病例注册(N3C)中电子健康记录的队列研究
medRxiv. 2023 Jan 5:2023.01.03.22284042. doi: 10.1101/2023.01.03.22284042.
8
Vaccine-Acquired SARS-CoV-2 Immunity versus Infection-Acquired Immunity: A Comparison of Three COVID-19 Vaccines.疫苗获得的SARS-CoV-2免疫力与感染获得的免疫力:三种COVID-19疫苗的比较
Vaccines (Basel). 2022 Dec 15;10(12):2152. doi: 10.3390/vaccines10122152.
Cureus. 2021 Jan 15;13(1):e12730. doi: 10.7759/cureus.12730.
4
Case report: a COVID-19 reactivation case.病例报告:COVID-19 再激活病例。
Pan Afr Med J. 2020 May 15;35(Suppl 2):35. doi: 10.11604/pamj.supp.2020.35.2.23326. eCollection 2020.
5
Fulminant myocarditis: COVID or not COVID? Reinfection or co-infection?暴发性心肌炎:是新冠感染所致还是非新冠感染?是再次感染还是合并感染?
Future Cardiol. 2021 Nov;17(8):1307-1311. doi: 10.2217/fca-2020-0237. Epub 2021 Feb 22.
6
Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers.巴西 30 名医护人员出现反复感染 COVID-19 现象,且病情加重。
J Infect. 2021 Mar;82(3):399-406. doi: 10.1016/j.jinf.2021.01.020. Epub 2021 Feb 13.
7
Case Reports of COVID 19 Recurrence.COVID-19 复发病例报告。
J Prim Care Community Health. 2021 Jan-Dec;12:2150132720982752. doi: 10.1177/2150132720982752.
8
Severe Reinfection With South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant 501Y.V2.南非严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体501Y.V2的严重再感染
Clin Infect Dis. 2021 Nov 16;73(10):1945-1946. doi: 10.1093/cid/ciab129.
9
A new positive SARS-CoV-2 test months after severe COVID-19 illness: reinfection or intermittent viral shedding?重症 COVID-19 痊愈数月后出现新型 SARS-CoV-2 检测阳性:再感染还是间歇性病毒脱落?
BMJ Case Rep. 2021 Feb 4;14(2):e240531. doi: 10.1136/bcr-2020-240531.
10
A case of SARS-CoV-2 reinfection in a patient with obstructive sleep apnea managed with telemedicine.一例经远程医疗管理的阻塞性睡眠呼吸暂停合并 SARS-CoV-2 再感染患者
BMJ Case Rep. 2021 Feb 1;14(2):e240496. doi: 10.1136/bcr-2020-240496.